APEN - Apollo Endosurgery, Inc.
| Previous Close | 3.3100 |
| Open | 3.3000 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 2900 |
| Day's Range | 3.3000 - 3.5800 |
| 52 Week Range | 2.5200 - 7.7000 |
| Volume | 2,125 |
| Avg. Volume | 13,053 |
| Market Cap | 72.818M |
| Beta (3Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8110 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
- Business Wire
Apollo Endosurgery, Inc. Announces Closing of $20 Million Private Placement of Convertible Debentures
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has closed its previously announced private placement of $20 million of unsecured convertible debentures to accredited and institutional investors. Interest on the debentures is payable semi-annually in common stock, or in kind in certain situations, at a rate per annum of 6.0%. At any time prior to maturity, the debentures are convertible into shares of Apollo’s common stock at a conversion price of $3.25, subject to certain customary adjustments.
- Business Wire
Apollo Endosurgery, Inc. Announces $20 Million Private Placement of Convertible Debentures
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has entered into definitive agreements with accredited investors, including officers and affiliates of certain directors of the company and institutional investors, to sell a principal amount of $20 million of unsecured convertible debentures in a private placement. Apollo expects to issue the debentures on or about August 12, 2019, subject to the satisfaction of customary closing conditions. Interest on the debentures will be payable semi-annually in common stock, or in kind in certain situations, at a rate per annum of 6.0%.
- Business Wire
Apollo Endosurgery, Inc. Reports Second Quarter 2019 Results
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET
- ACCESSWIRE
Apollo Endosurgery, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 23, 2019 / Apollo Endosurgery, Inc. (NASDAQ: APEN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 4:30 ...
- Business Wire
Apollo Endosurgery, Inc. to Report Second Quarter Results on July 23, 2019
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended June 30, 2019 on Tuesday, July 23, 2019, after the U.S.
- Simply Wall St.
What Investors Should Know About Apollo Endosurgery, Inc.'s (NASDAQ:APEN) Financial Strength
Apollo Endosurgery, Inc. (NASDAQ:APEN) is a small-cap stock with a market capitalization of US$69m. While investors...
- Business Wire
Apollo Endosurgery Announces Completion of Patient Enrollment for the Multi-Center ESG Randomized Interventional Trial (MERIT)
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the final patient has been enrolled in the Multi-Center ESG Randomized Interventional Trial (MERIT). The US based, prospective randomized multi-center-controlled trial is evaluating the effectiveness of the endoscopic sleeve gastroplasty (“ESG”) procedure. ESG is an endoscopic minimally invasive weight loss procedure based on full-thickness endoscopic suturing using Apollo’s OverStitch™ device.
- Business Wire
Apollo Endosurgery, Inc. to Present at the JMP Securities 2019 Life Sciences Conference
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today that company management is scheduled to present at the JMP Securities 2019 Life Sciences Conference being held June 19-20, 2019 at the St.
- Business Wire
Apollo Endosurgery Announces US Labeling Update on the ORBERA® Intragastric Balloon System
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced today that it has received FDA approval for its proposed labeling updates for the ORBERA® Intragastric Balloon System. The goal of the labeling updates is to improve patient safety and these will take effect immediately. The labeling updates improve patient safety by providing further definition and guidance on the appropriate use of the ORBERA® Intragastric Balloon System and patient selection.
- Simply Wall St.
Volatility 101: Should Apollo Endosurgery (NASDAQ:APEN) Shares Have Dropped 48%?
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
- Business Wire
Apollo Endosurgery Announces DDW 2019 Clinical Highlights
Apollo Endosurgery, Inc. , a leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced highlights from DDW 2019 which took place from May 18th to May 21st in San Diego.
- Business Wire
Apollo Endosurgery to Participate in Digestive Disease Week® 2019
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today its participation during Digestive Disease Week 2019 (“DDW”). Apollo’s OverStitch™ Endoscopic Suturing System and ORBERA® Intragastric Balloon, will be featured in 40 clinical presentations that demonstrate the effectiveness of OverStitch and ORBERA when used across a number of diverse clinical needs. Apollo will also feature Overstitch Sx, its latest endoscopic suturing device designed for compatibility with single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm.
- Business Wire
Apollo Endosurgery, Inc. Reports First Quarter 2019 Results
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET
- Business Wire
Apollo Endosurgery, Inc. to Report First Quarter Results on May 2, 2019
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended March 31, 2019 on Thursday, May 2, 2019, after the U.S.
- Zacks
Apollo Endosurgery (APEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apollo Endosurgery (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Did Apollo Endosurgery, Inc. (NASDAQ:APEN) Insiders Buy Up More Shares?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunatel...
- Business Wire
Apollo Endosurgery Appoints John Barr to Board of Directors
The Board of Directors of Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that John Barr has been appointed to Apollo’s Board of Directors as an independent director, effective immediately. Mr. Barr will join 9 other directors, a majority of whom are independent under the rules and regulations of the United States Securities and Exchange Commission, and will serve as a member of the Audit and Nominating and Governance Committees. “John is a highly accomplished leader in the medical device field and an experienced board member who brings a wealth of executive leadership skills and experience to our board,” said Rich Meelia, Chairman of Apollo’s Board of Directors.
- Business Wire
Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2018 Results
Conference Call to Discuss Results Today at 7:30 a.m. CT / 8:30 a.m. ET
- Business Wire
Apollo Endosurgery, Inc. to Report Fourth Quarter Results on March 18, 2019
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter ended December 31, 2018 on Monday, March 18, 2019, before the U.S.
- Simply Wall St.
Does Market Volatility Impact Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Share Price?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you own shares in Apollo Endosurgery, Inc. (NASDAQ:APEN) thenRead More...
- Business Wire
Apollo Endosurgery Announces Publication of Outcomes of Endoscopic Sleeve Gastroplasty (ESG) in 1,000 Consecutive Patients
Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced the publication of Outcomes of Endoscopic Gastroplasty in 1,000 Consecutive Patients from a single center - King Saud University, Riyadh, Saudi Arabia featured in Gastrointestinal Endoscopy - https://doi.org/10.1016/j.gie.2018.12.012.
- Simply Wall St.
Apollo Endosurgery, Inc. (NASDAQ:APEN) Investors Are Paying Above The Intrinsic Value
In this article I am going to calculate the intrinsic value of Apollo Endosurgery, Inc. (NASDAQ:APEN) by taking the expected future cash flows and discounting them to their present value. Read More...
- Simply Wall St.
What does Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Balance Sheet Tell Us About Its Future?
Apollo Endosurgery, Inc. (NASDAQ:APEN) is a small-cap stock with a market capitalization of US$77m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...
- Business Wire
Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line
Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc. (“ReShape”) (RSLS). The definitive transaction agreements were signed and closed simultaneously yesterday, December 17, 2018. This transaction will allow Apollo to focus all its efforts on growing the clinical adoption of its Endo-bariatric product offerings, which consists of its OverStitch Endoscopic Suturing Systems and the Orbera Intragastric Balloon technologies.
- GlobeNewswire
Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
